W
Walter J. Curran
Researcher at Emory University
Publications - 751
Citations - 45336
Walter J. Curran is an academic researcher from Emory University. The author has contributed to research in topics: Radiation therapy & Lung cancer. The author has an hindex of 86, co-authored 742 publications receiving 38522 citations. Previous affiliations of Walter J. Curran include Fox Chase Cancer Center & Washington University in St. Louis.
Papers
More filters
Journal ArticleDOI
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
David W. Andrews,Charles B. Scott,Paul W. Sperduto,Adam E. Flanders,Laurie E. Gaspar,Michael C. Schell,Maria Werner-Wasik,W. Demas,J. Ryu,Jean-Paul Bahary,Luis Souhami,Marvin Rotman,Minesh P. Mehta,Walter J. Curran +13 more
TL;DR: WBRT and stereotactic radiosurgery should, therefore, be standard treatment for patients with a single unresectable brain metastasis and considered for Patients with two or three brain metastases.
Journal ArticleDOI
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert,James J. Dignam,Terri S. Armstrong,Terri S. Armstrong,Jeffrey S. Wefel,Deborah T. Blumenthal,Michael A. Vogelbaum,Howard Colman,Arnab Chakravarti,Stephanie L. Pugh,Minhee Won,Robert Jeraj,Paul D. Brown,Kurt A. Jaeckle,David Schiff,Volker W. Stieber,David Brachman,Maria Werner-Wasik,Ivo W. Tremont-Lukats,Erik P. Sulman,Kenneth Aldape,Walter J. Curran,Minesh P. Mehta +22 more
TL;DR: First-line use of bevacizumab did not improve overall survival in patients with newly diagnosed glioblastoma, and progression-free survival was prolonged but did not reach the prespecified improvement target.
Journal ArticleDOI
Lung cancer: current therapies and new targeted treatments
Fred R. Hirsch,Giorgio V. Scagliotti,James L. Mulshine,Regina Kwon,Walter J. Curran,Yi-Long Wu,Luis Paz-Ares +6 more
TL;DR: Prevention and early detection of lung cancer with an emphasis on lung cancer screening is discussed, and the importance of smoking prevention and cessation is acknowledged.
Journal ArticleDOI
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study
Jeffrey D. Bradley,Rebecca Paulus,Ritsuko Komaki,Gregory A. Masters,George R. Blumenschein,Steven E. Schild,Jeffrey A. Bogart,Chen Hu,Kenneth M. Forster,Anthony M. Magliocco,V.S. Kavadi,Yolanda I. Garces,Samir Narayan,Puneeth Iyengar,Cliff G. Robinson,Raymond B. Wynn,Christopher Koprowski,Joanne Meng,Jonathan J. Beitler,Rakesh Gaur,Walter J. Curran,Hak Choy +21 more
TL;DR: Overall survival after standard-dose versus high-dose conformal radiotherapy with concurrent chemotherapy and the addition of cetuximab to concurrent chemoradiation for patients with inoperable stage III non-small-cell lung cancer was compared.
Journal ArticleDOI
Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
Anne Auperin,Cécile Le Péchoux,Estelle Rolland,Walter J. Curran,Kiyoyuki Furuse,Pierre Fournel,José Belderbos,Gerald H. Clamon,Hakki Cuneyt Ulutin,Rebecca Paulus,Takeharu Yamanaka,Marie-Cecile Bozonnat,Apollonia L.J. Uitterhoeve,Xiaofei Wang,Lesley A. Stewart,Rodrigo Arriagada,Sarah Burdett,Jean-Pierre Pignon +17 more
TL;DR: Concomitant radiochemotherapy, as compared with sequential radiochemicalotherapy, improved survival of patients with locally advanced NSCLC, primarily because of a better locoregional control, but at the cost of manageable increased acute esophageal toxicity.